samedan logo

 
 
spacer
home > ebr > winter 2003 > drug discovery in the post-genomic era
PUBLICATIONS
European Biopharmaceutical Review

Drug Discovery in the Post-Genomic Era

2003 marked the completion of the human genome project and we now find ourselves in a post-genomic era, trying to understand and utilise a previously unimaginable amount of biological information. Scientists have the daunting task of finding new ways to use the human genome sequence for the benefit of humanity - to develop new drugs and to find better ways to combat disease.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Steve Lombardi, Vice President of Corporate Development at Affymetrix, Inc

Steve Lombardi is Vice President of Corporate Development at Affymetrix, Inc. He has made significant progress in moving early-stage, advanced technology out to customers. Prior to joining Affymetrix, Steve was Senior Vice President of Applications and Products for Applied Biosystems, managing strategic marketing and applications R&D. He earned his BA in Biology from Merrimack College.

spacer
Steve Lombardi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement